L-DOPA methylation generates homocysteine by the action of catechol-O-methyltransferase (COMT), and hyperhomocysteinemia might contribute to the loss of therapeutic effect of L-DOPA over time due to the negative allosteric properties of homocysteine on D2 receptors [102]. The gene discussed is COMT; the disease is hyperhomocysteinemia.